Business context and reporting period
This unaudited Form 10-Q covers the quarter and six months ended June 30, 2014. Important identity note: although the request identifies Gyre Therapeutics, Inc., the filing is for Targacept, Inc.—a clinical-stage biopharmaceutical company developing neuronal nicotinic receptor candidates. It had no approved products. The company said it was shifting focus toward selectively adding non-nicotinic opportunities after disappointing trial outcomes and discontinuing development programs.
Financial performance and position
Amounts below are in U.S. dollars; financial statement figures are in millions unless stated otherwise.
| Metric | Q2 2014 | Q2 2013 | Six months 2014 | Six months 2013 |
|---|---|---|---|---|
| Operating revenue | $0.036 | $0 | $0.123 | $3.536 |
| Research and development expense | $5.408 | $9.454 | $14.488 | $17.774 |
| General and administrative expense | $2.867 | $3.034 | $5.630 | $6.524 |
| Operating loss | $(8.239) | $(12.488) | $(19.995) | $(20.762) |
| Net loss | $(8.136) | $(12.371) | $(23.135) | $(20.437) |
| Net loss per share | $(0.24) | $(0.37) | $(0.69) | $(0.61) |
- Operating margins are not meaningful given minimal grant revenue and the company’s development-stage losses.
- Six-month operating cash use was $23.759 million, versus $19.735 million a year earlier. Investing activities provided $9.419 million and financing activities provided $3.272 million; cash and cash equivalents fell $11.068 million to $43.417 million.
- At June 30, cash, cash equivalents and marketable securities totaled $122.8 million, down from $143.8 million at December 31, 2013. Total assets were $124.515 million, liabilities $7.497 million, and stockholders’ equity $117.018 million.
- Debt was $699,000, all classified as current; the company reported no remaining borrowing capacity under its equipment loan. No separate liquidity ratio is provided in the filing.
Material changes versus the prior comparable period
- Q2 R&D expense decreased $4.046 million, principally because the TC-5619 schizophrenia study had been completed in 2013. For the six-month period, R&D expense fell $3.286 million, reflecting lower TC-5619 and infrastructure costs, partly offset by spending on TC-5214 and TC-6499.
- Six-month revenue fell $3.413 million because 2013 included recognition of $3.536 million of previously deferred AstraZeneca revenue after AstraZeneca terminated TC-1734 from the collaboration. 2014 revenue consisted of grant revenue.
- Six-month net loss increased $2.698 million despite a lower operating loss; 2014 included $3.457 million of income tax expense, principally associated with an examination adjustment and excess stock-option tax deductions.
Outlook, commentary, and risks
- Management expected cash and marketable securities of approximately $107 million at December 31, 2014. It anticipated about $6.4 million of remaining-2014 cash payments to close out the TC-1734 and TC-5214 trials. The filing does not provide a clear cash-runway estimate.
- In July 2014, after quarter-end, the company reported that TC-1734’s Phase 2b Alzheimer’s trial missed its primary endpoint and TC-5214’s Phase 2b overactive-bladder trial missed one of two primary endpoints. It said it had no further development plans for either candidate in those indications. These are post-quarter updates.
- TC-6499 was in an exploratory study for diabetic gastroparesis. AstraZeneca controlled substantially the development decisions and activities for AZD1446; potential milestone payments were uncertain, and management did not expect the collaboration to be a significant source of future funds.
- The company anticipated future losses and said existing resources might not fund completion of its development programs. Additional financing or collaborations may be needed; financing may be unavailable or dilutive, and the company could have to delay, reduce, or eliminate programs or relinquish rights.
- Other key risks include clinical and regulatory uncertainty, trial execution and enrollment, dependence on collaborators, intellectual-property protection, and potential limits on use of tax-loss carryforwards. Management reported disclosure controls effective and no material quarterly change in internal control over financial reporting.
Important facts for investors to verify
- Confirm the intended issuer: this filing identifies Targacept, Inc., not Gyre Therapeutics, Inc.
- Review subsequent disclosures on the TC-1734 and TC-5214 trial results and any changes to the development pipeline or operating plan.
- Track actual cash use against management’s year-end cash-and-investments estimate and the stated trial close-out costs.
- Check the timing and status of TC-6499 and AstraZeneca’s AZD1446 program; milestone revenue is contingent and uncertain.
- Reconcile the filing’s tax-deduction figures: the financial-statement note reports $3.497 million remaining, while MD&A reports $3.9 million.